The Business Research Company’s report on the Methylmalonic Acidemia (MMA) Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the methylmalonic acidemia (mma) market in recent years?
The increasing incidence of metabolic disorders and vitamin deficiencies is expected to propel the growth of the methylmalonic acidemia (MMA) market going forward. Metabolic disorders are a group of conditions in which the body has trouble processing certain nutrients, producing energy, or regulating chemical reactions within cells. Vitamin deficiencies occur when the body lacks enough specific vitamins to perform normal functions. The rise in metabolic disorders and vitamin deficiencies is due to unhealthy diets, sedentary lifestyles, and increased stress levels. Modern diets are often high in processed foods, sugars, and unhealthy fats while low in essential nutrients, leading to deficiencies in vitamins and minerals. Metabolic disorders and vitamin deficiencies, particularly vitamin B12 deficiency, impair methylmalonyl-CoA metabolism, accumulating methylmalonic acid and exacerbating methylmalonic acidemia (MMA). For instance, in November 2024, according to the National Institutes of Health, a US-based government agency, the prevalence of vitamin B12 deficiency increased from 4.6% to 5.2%, representing an additional 507 cases between the third and fourth quarters of 2023. Therefore, the increasing incidence of metabolic disorders and vitamin deficiencies drives the growth of the methylmalonic acidemia (MMA) market.
Access Your Free Sample of the Global Methylmalonic Acidemia (MMA) Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22057&type=smp
What is the projected market size of the methylmalonic acidemia (mma) industry, and how is it expected to grow?
The methylmalonic acidemia (MMA) market size has grown strongly in recent years. It will grow from $9.39 billion in 2024 to $9.97 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to the increasing incidence of metabolic disorders and vitamin deficiencies, increased healthcare expenditure, rise in health consciousness, increasing prevalence of genetic disorders, and growing demand from various end-user industries.
The methylmalonic acidemia (MMA) market size is expected to see strong growth in the next few years. It will grow to $12.50 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to increasing newborn screening programs, increased awareness among healthcare professionals, a rise in gene therapy advancements, rising investments in rare disease research, and increasing availability of specialized treatments. Major trends in the forecast period include advancements in gene editing technologies, advanced diagnostic techniques for early detection, advancements in enzyme replacement therapies, adoption of precision medicine approaches, and adoption of newborn genetic screening programs.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22057&type=smp
Who are the key players driving competition in the methylmalonic acidemia (mma) market?
Major companies operating in the methylmalonic acidemia (MMA) market are Moderna Inc., Lonza Group Ltd., Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Wockhardt Limited, Spectrum Chemical Manufacturing Corp., Asklepios BioPharmaceutical Inc. (AskBio), Selecta Biosciences Inc., BTG International Inc., BridgeBio Pharma Inc., VectivBio Holding AG, Supriya Lifescience Ltd., Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., AdvaCare Pharma USA LLC, LogicBio Therapeutics Inc., HemoShear Therapeutics LLC, Manus Aktteva Biopharma LLP, Deccan Nutraceuticals Pvt. Ltd.
What key trends are expected to drive the metal power transmission chain market during the forecast period?
Major companies operating in the methylmalonic acidemia (MMA) market are focusing on developing innovative solutions, such as mRNA-based therapies, to improve treatment outcomes by targeting the underlying genetic causes of MMA and enhancing enzyme function to reduce the accumulation of toxic metabolites in affected individuals. mRNA-based therapies are a type of treatment that uses messenger RNA to instruct cells to produce specific proteins that can help prevent or treat diseases, such as genetic disorders or infections. For instance, In June 2024, Moderna, Inc., a US-based pharmaceutical and biotechnology company, received U.S. Food and Drug Administration (FDA) approval for including mRNA-3705 in the START pilot program, marking a significant step in advancing treatments for rare diseases. mRNA-3705 is an investigational therapy for methylmalonic acidemia (MMA) caused by MUT deficiency, designed to restore the missing enzyme using mRNA technology. The therapy leverages Moderna’s proprietary lipid nanoparticle (LNP) system, also utilized in the mRNA-3927 program for propionic acidemia. The FDA has granted mRNA-3705 orphan drugs, fast track, and rare pediatric disease designations, facilitating its accelerated development and clinical progress.
Which key geographies are driving the growth of the methylmalonic acidemia (mma) market?
North America was the largest region in the methylmalonic acidemia (MMA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methylmalonic acidemia (MMA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/methylmalonic-acidemia-mma-global-market-report
What are the key segments driving growth in the methylmalonic acidemia (mma) market?
The methylmalonic acidemia (MMA) market covered in this report is segmented –
1) By Indication: Acidosis, Ketosis, Hyperammonemia, Hypoglycaemia, Hyperglycaemia, Neutropenia, Other Indications
2) By Disorder Type: Homocystinuria, Isolated Methylmalonic Acidurias, Combined methylmalonic Aciduria
3) By Distribution Channel: Hospitals, Pharmacies, Clinics, Other Distribution Channels
Subsegments:
1) By Acidosis: Metabolic Acidosis, Lactic Acidosis
2) By Ketosis: Starvation-Induced Ketosis, Diabetic Ketoacidosis
3) By Hyperammonemia: Acute Hyperammonemia, Chronic Hyperammonemia
4) By Hypoglycemia: Fasting Hypoglycemia, Reactive Hypoglycemi
5) By Hyperglycemia: Transient Hyperglycemia, Persistent Hyperglycemia
6) By Neutropenia: Severe Neutropenia, Cyclic Neutropenia
7) By Other Indications: Failure to Thrive, Developmental Delays, Neurological Symptoms, Renal Dysfunction
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22057
How is the methylmalonic acidemia (mma) market defined, and what are its core characteristics?
Methylmalonic acidemia (MMA) is a rare, inherited metabolic disorder in which the body is unable to properly break down specific proteins and fats due to a deficiency in the enzyme methylmalonyl-CoA mutase or a related coenzyme, vitamin B12. The symptoms of MMA can vary in severity but often include vomiting, lethargy, poor feeding, developmental delay, seizures, and failure to thrive.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
